New research out of Harvard Medical School suggests that lithium deficiency may be a key driver of Alzheimer’s disease and a promising target for early diagnosis and treatment. Harvard’s Office of Technology Development has protected the innovations related to this research and is actively seeking industry partners for commercialization to advance these discoveries.

GC Therapeutics (GCTx), a Harvard startup, announced its launch to scale and its technology TFome™, the world’s first “plug and play” induced pluripotent stem cell (iPSC) programming platform for cell therapies in multiple therapeutic areas. 

Harvard researchers have pioneered a groundbreaking method for generating large numbers of adult skeletal-muscle satellite cells, also known as muscle stem cells, in vitro.

The Wyss Institute at Harvard University announced that Ropirio Therapeutics, Inc. (Ropirio) has secured a worldwide, exclusive license from Harvard’s Office of Technology Development (OTD) and Boston University (BU)’s Technology Development office for novel molecules that activate the lymphatic system.